Rocket Pharmaceuticals Inc Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Transcript
Good afternoon, ladies and gentlemen, and welcome to the Rocket Pharmaceuticals Conference Call, discussing the Phase I data results for Rocket Pharmaceuticals Danon disease program presented today at the Heart Failure Society of America Annual Scientific Meeting. As a reminder, this conference is being recorded. I will now turn the call over to your host, Ms. Jessie Yeung, Rocket's Vice President of Investor Relations and Corporate Communications. You may begin your conference.
Thank you, operator, and good morning, everyone. Thanks for joining our call today to discuss the Phase 1 results of our Danon disease program. This is Jessie Yeung, Vice President of Investor Relations and Corporate Finance at Rocket Pharmaceuticals. With me on the line today is Dr. Gaurav Shah, CEO of Rocket Pharma. We also have Kinnari Patel, President and COO of Rocket; and Jonathan Schwartz, our CMO, for the Q&A session. Before we begin, I would like to briefly discuss the use of forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |